BR-6002 by Boryung Pharmaceutical for Duodenal Ulcer: Likelihood of Approval
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BR-6002 overview
BR-6002 is under development for the treatment of cardiovascular disease, gastric ulcers and duodenal ulcers. It is administered through oral route.
Boryung Pharmaceutical overview
Boryung Pharmaceutical (Boryung)is a pharmaceutical company. It manufactures and distributes pharmaceutical products including cardiovascular, anticancer and gastrointestinal drugs. The company offers products such as kanarb, kanab plus, dukarb, dukaro, akarb, VCS inj, velkin injection, alimxid injection, effcil injection, oxalitin, neoplatin, EP mycin and AD mycin. Boryung gastrointestinal includes gelfosM for the treatment of hypogastric acidity, heartburn, gastric and duodenal ulcer, gastritis, gastralgia and nausea. The company also provides marketed API. Boryung is headquartered in Seoul, South Korea.
For a complete picture of BR-6002’s drug-specific PTSR and LoA scores, buy the report here.
Source link
#BR6002 #Boryung #Pharmaceutical #Duodenal #Ulcer #Likelihood #Approval